AU2005303893A1 - Pyrimidine compounds as histamine modulators - Google Patents

Pyrimidine compounds as histamine modulators Download PDF

Info

Publication number
AU2005303893A1
AU2005303893A1 AU2005303893A AU2005303893A AU2005303893A1 AU 2005303893 A1 AU2005303893 A1 AU 2005303893A1 AU 2005303893 A AU2005303893 A AU 2005303893A AU 2005303893 A AU2005303893 A AU 2005303893A AU 2005303893 A1 AU2005303893 A1 AU 2005303893A1
Authority
AU
Australia
Prior art keywords
pyrimidine
furo
chloro
benzo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005303893A
Other languages
English (en)
Inventor
Sue Cramp
Hazel Joan Dyke
Neil Harris
Christopher Higgs
Steve Price
Stephen Wren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argenta Discovery Ltd
Original Assignee
Argenta Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0424972A external-priority patent/GB0424972D0/en
Priority claimed from EP05022665A external-priority patent/EP1776982A1/en
Application filed by Argenta Discovery Ltd filed Critical Argenta Discovery Ltd
Publication of AU2005303893A1 publication Critical patent/AU2005303893A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005303893A 2004-11-11 2005-11-11 Pyrimidine compounds as histamine modulators Abandoned AU2005303893A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0424972A GB0424972D0 (en) 2004-11-11 2004-11-11 Pyrimidine compounds
GB0424972.8 2004-11-11
EP05022665A EP1776982A1 (en) 2005-10-18 2005-10-18 Pyrimidine compounds as histamine modulators
EP05022665.3 2005-10-18
PCT/EP2005/012087 WO2006050965A1 (en) 2004-11-11 2005-11-11 Pyrimidine compounds as histamine modulators

Publications (1)

Publication Number Publication Date
AU2005303893A1 true AU2005303893A1 (en) 2006-05-18

Family

ID=35658998

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005303893A Abandoned AU2005303893A1 (en) 2004-11-11 2005-11-11 Pyrimidine compounds as histamine modulators

Country Status (6)

Country Link
US (1) US20080269239A1 (https=)
EP (1) EP1812113A1 (https=)
JP (1) JP2008519794A (https=)
AU (1) AU2005303893A1 (https=)
CA (1) CA2586316A1 (https=)
WO (1) WO2006050965A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
EP1860109A1 (en) * 2006-05-24 2007-11-28 Cellzome (UK) Ltd. Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders
WO2007090854A1 (en) * 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders
TW200815054A (en) * 2006-06-19 2008-04-01 Otsuka Pharma Co Ltd Methods of using a thiazole derivative
KR20090028819A (ko) * 2006-07-11 2009-03-19 얀센 파마슈티카 엔.브이. 히스타민 ｈ４ 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
CA2705719C (en) 2007-09-14 2016-10-11 Janssen Pharmaceutica N.V. Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
PE20090978A1 (es) * 2007-10-30 2009-07-13 Palau Pharma Sa DERIVADOS DE FURO {3,2-d} PIRIMIDINA
AR069869A1 (es) * 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
WO2009115496A1 (en) * 2008-03-17 2009-09-24 Palau Pharma, S. A. Furo [3, 2-d] pyrimidine derivatives as h4 receptor antagonists
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
MX2010013726A (es) 2008-06-12 2011-01-14 Janssen Pharmaceutica Nv Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina.
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
TW201500358A (zh) 2010-12-16 2015-01-01 赫夫門羅氏藥廠股份有限公司 三環ｐｉ３ｋ抑制劑化合物及其使用方法
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
CN105103327B (zh) * 2013-03-26 2018-09-07 株式会社半导体能源研究所 发光元件、化合物、有机化合物、显示模块、照明模块、发光装置、显示装置、照明装置以及电子设备
KR102287012B1 (ko) * 2014-05-28 2021-08-09 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
KR20250065420A (ko) 2015-12-25 2025-05-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 화합물, 발광 소자, 표시 장치, 전자 기기, 및 조명 장치
CA3023867A1 (en) * 2016-05-09 2017-11-16 Biogaia Ab Selection of bacterial strains useful in allergy treatment
CN115275032B (zh) 2016-12-28 2025-12-23 株式会社半导体能源研究所 发光元件、有机化合物、发光装置、电子设备及照明装置
JP2019006763A (ja) 2017-06-22 2019-01-17 株式会社半導体エネルギー研究所 有機化合物、発光素子、発光装置、電子機器、および照明装置
CA3125625A1 (en) * 2019-01-04 2020-07-09 Bellbrook Labs, Llc Inhibitors of cgas activity as therapeutic agents
US20240059712A1 (en) * 2022-03-09 2024-02-22 Risen (Suzhou) Pharma Tech Co., Ltd. Bifunctional compounds and pharmaceutical uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755583A (en) * 1970-06-05 1973-08-28 Chas0!nhx
JPH06220059A (ja) * 1993-01-28 1994-08-09 Tanabe Seiyaku Co Ltd 縮合ピリミジン誘導体及びその製法
EP1373204B1 (en) * 2001-03-09 2016-10-26 Janssen Pharmaceuticals, Inc. Heterocyclic compounds
EP1543011B1 (en) * 2002-09-06 2006-05-03 Janssen Pharmaceutica N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
JP4845736B2 (ja) * 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤

Also Published As

Publication number Publication date
US20080269239A1 (en) 2008-10-30
CA2586316A1 (en) 2006-05-18
EP1812113A1 (en) 2007-08-01
WO2006050965A1 (en) 2006-05-18
WO2006050965A8 (en) 2006-08-31
JP2008519794A (ja) 2008-06-12

Similar Documents

Publication Publication Date Title
AU2005303893A1 (en) Pyrimidine compounds as histamine modulators
US11091484B2 (en) Tricyclic heterocycles as BET protein inhibitors
CN104884458B (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
JP5680082B2 (ja) β−アミロイド産生低減のための化合物
JP6523251B2 (ja) Ｃ−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途
KR100883003B1 (ko) 알츠하이머병의 치료를 위한 글라이신 수송체1(ｇｌｙｔ-1) 억제제로서 바이- 및 트라이사이클릭 치환된페닐 메탄온
EP2403853B1 (en) Pyrrolopyrimidines used as kinase inhibitors
JP5609861B2 (ja) キノキサリン化合物
CN104755083B (zh) 氨基烷基哌嗪的脲和酰胺衍生物及其用途
WO2009077956A2 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Нh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
AU2008277676A1 (en) Heterocyclic compounds useful as MK2 inhibitors
KR20130106358A (ko) 피라졸로퀴놀린 화합물
KR20190044054A (ko) 신규 화합물 또는 그의 약학적으로 허용가능한 염
US20230373960A1 (en) Indoline compounds and derivatives as egfr inhibitors
US20240352018A1 (en) SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG
JP4890446B2 (ja) ドーパミンｄ３受容体に対してアフィニティーを有する化合物およびその使用
AU2006298857A1 (en) Pyrimidine compounds for the treatment of inflammatory disorders
WO2011111817A1 (ja) ベンゾアゼピン化合物
AU2006323982A1 (en) Chromone derivatives useful as antagonists of VR1 receptors
US20140378451A1 (en) Cannabinoid-2-Receptor Agonists
US20220372041A1 (en) Quinoxaline derivatives
EP1776982A1 (en) Pyrimidine compounds as histamine modulators
CN121311486A (zh) Erbb2抑制剂
MX2010011136A (es) Derivados de pirrolo [2,3-d] pirimidin-2-il-amina como inhibidores pkc-theta.

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period